Literature DB >> 2919950

Serotonergic responsivity in male young adults with autistic disorder. Results of a pilot study.

P A McBride1, G M Anderson, M E Hertzig, J A Sweeney, J Kream, D J Cohen, J J Mann.   

Abstract

Altered serotonergic function has been postulated to exist in autistic disorder. Central serotonergic responsivity was assessed with a neuroendocrine challenge test in seven male young adults with autistic disorder and in seven age- and gender-matched healthy controls. Binding indexes and physiologic responsivity of the platelet serotonin-2 (5-HT2) receptor complex were also measured, as was whole-blood serotonin content. Compared with controls, autistic subjects had substantially blunted prolactin release in response to a 60-mg oral dose of fenfluramine hydrochloride, an indirect serotonin agonist [corrected]. Furthermore, the magnitude of serotonin-amplified platelet aggregation, mediated by the platelet 5-HT2 receptor complex, was reduced in the autistic group, as was the mean number of platelet 5-HT2 receptor sites. Among autistic subjects, fenfluramine-induced prolactin release correlated positively with the serotonin-amplified platelet aggregation response and negatively with whole-blood serotonin content. The results of the present study are compatible with the hypothesis that central serotonergic responsivity is decreased in male autistic young adults. Correlations between central and peripheral serotonergic measures in autistic subjects suggest that systemic alterations in serotonergic function may occur in autism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2919950     DOI: 10.1001/archpsyc.1989.01810030019003

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  38 in total

Review 1.  Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB.

Authors:  Ragy R Girgis; Mark Slifstein; Xiaoyan Xu; W Gordon Frankle; Evdokia Anagnostou; Stacey Wasserman; Lauren Pepa; Alexander Kolevzon; Anissa Abi-Dargham; Marc Laruelle; Eric Hollander
Journal:  Psychiatry Res       Date:  2011-11-12       Impact factor: 3.222

Review 3.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

4.  Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels.

Authors:  Ana M Coutinho; Inês Sousa; Madalena Martins; Catarina Correia; Teresa Morgadinho; Celeste Bento; Carla Marques; Assunção Ataíde; Teresa S Miguel; Jason H Moore; Guiomar Oliveira; Astrid M Vicente
Journal:  Hum Genet       Date:  2007-01-03       Impact factor: 4.132

Review 5.  Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.

Authors:  Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

6.  Whole Blood Serotonin Levels and Platelet 5-HT2A Binding in Autism Spectrum Disorder.

Authors:  Elizabeth Aaron; Alicia Montgomery; Xinguo Ren; Stephen Guter; George Anderson; Ana M D Carneiro; Suma Jacob; Matthew Mosconi; Ghanshyam N Pandey; Edwin Cook; Jeremy Veenstra-VanderWeele
Journal:  J Autism Dev Disord       Date:  2019-06

7.  Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial.

Authors:  S H Fatemi; G M Realmuto; L Khan; P Thuras
Journal:  J Autism Dev Disord       Date:  1998-08

Review 8.  The serotonin system in autism spectrum disorder: From biomarker to animal models.

Authors:  C L Muller; A M J Anacker; J Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

9.  Plasma androgens in autism.

Authors:  S Tordjman; G M Anderson; P A McBride; M E Hertzig; M E Snow; L M Hall; P Ferrari; D J Cohen
Journal:  J Autism Dev Disord       Date:  1995-06

10.  Modeling rare gene variation to gain insight into the oldest biomarker in autism: construction of the serotonin transporter Gly56Ala knock-in mouse.

Authors:  Jeremy Veenstra-Vanderweele; Tammy N Jessen; Brent J Thompson; Michelle Carter; Harish C Prasad; Jennifer A Steiner; James S Sutcliffe; Randy D Blakely
Journal:  J Neurodev Disord       Date:  2009-06       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.